Navigation Links
DARA Announces Surgi-Vision Agreement with Boston Scientific Corporation
Date:4/16/2008

RALEIGH, N.C., April 16 /PRNewswire-FirstCall/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today that Surgi-Vision, Inc., a privately held company of which DARA Biosciences owns approximately 9.8% of the outstanding shares, has entered into a licensing and development agreement with Boston Scientific Corporation (NYSE: BSX) for magnetic resonance imaging (MRI)-safe technology.

Boston Scientific issued a press release yesterday announcing a licensing and development arrangement for magnetic resonance imaging (MRI)-safe technology. Physician implanters have consistently mentioned MRI-safe cardiac devices as a primary unmet clinical need. Under the arrangement, Boston Scientific will gain access to Surgi-Vision's development capabilities and will obtain a license to Surgi-Vision's intellectual property for potential use in its implantable cardiac devices. The two companies will work jointly to develop a commercial application of Surgi-Vision's technology. Previously, Boston Scientific and Surgi-Vision entered into a separate licensing and development agreement, in the area of neuromodulation, in December 2005. A complete copy of Boston Scientific's press release can be found at Boston Scientific's website (http://www.bostonscientific.com ).

DARA has been an investor in Surgi-Vision since 2004. Surgi-Vision is a leader in the development of next generation MRI technologies. In addition to its expertise in MRI-safety for implanted medical devices
'/>"/>

SOURCE DARA BioSciences
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...f shifting around body fat to flatten your tummy a...locking that ample fat? According to an internati...ome reality. The study, published online in Natur...an cosmetic and reconstructive surgery and treatme...
...alth Scientific and Industrial Research Organisati...cy, says it has developed a blood test that has t...est, hailed as the first of its kind, essentially ...n's DNA and can point to the likelihood of certain...
...ctive study suggests that ovarian germ cell tumour... and fertility-sparing surgery may retain their m...study, published in the Journal of Clinical Oncolo...eproductive and sexual concerns, survivors were mo...
...t Victoria Beckham has imposed a strict diet regim...our that is to begin later this year. The new ri...e four members to go on a diet of edamame beans, s... and all this combined with 200 sit ups a day. "V...
Other Medicine News:Health News:Stressed Mice may Hold Clue to How Fat is Stored: Study 2Health News:A Blood Test Developed in Australia to Repair DNA Damage 2Health News:Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability 2Health News:Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability 3
(Date:9/5/2008)... 5 /PRNewswire-USNewswire/ -- The Florida,Technolo...d Florida,Atlantic University researcher Dr. Herbe... of the Center for Molecular Biology and,Biotechno... and CHS,Resources LLC (CHS), $184,294 as part of ...sistance Grant program (SURECAG). SURECAG was,esta...
(Date:9/5/2008)...lif., Sept. 5 /- SARcode,Co...cule LFA-1 inhibitors,to treat inflammatory diseas...S) today announced SARcode,s initiation of a Phase...t candidate for T-cell mediated ophthalmic,disease...ement providing,SARcode with an exclusive license ...
(Date:9/4/2008)...ept. 4 /- Cytopia Limited (ASX:,CYT) ...r its Phase Ib/II,study of CYT997, the company,s n...ents with an aggressive form of brain cancer known...cal trial is the first Phase II efficacy study in ...ompany and the second in its,suite of Phase II stu...
(Date:9/4/2008)...Man(R) real-time PCR testing for the diagnostic ...alif., Sept. 4 /- The U.S. Food & Dru...S(R) TaqMan(R) HBV Test,the first assay for quant...,The test uses Roche,s real-time PCR technology to... patient,s blood. Doctors may use viral load,testi...
Breaking Medicine Technology:Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3The Polls are Open 21 America Votes to Decide Which Hospital is the Most Deserving of Siemens Newest MRI Technology 7786 1The Polls are Open 21 America Votes to Decide Which Hospital is the Most Deserving of Siemens Newest MRI Technology 7786 2The Polls are Open 21 America Votes to Decide Which Hospital is the Most Deserving of Siemens Newest MRI Technology 7786 3Neurochem announces eprodisate 28KIACTA 28TM 29 29 receives acknowledgement of complete response and is granted Class 2 review 7781 1Neurochem announces eprodisate 28KIACTA 28TM 29 29 receives acknowledgement of complete response and is granted Class 2 review 7781 2Neurochem announces eprodisate 28KIACTA 28TM 29 29 receives acknowledgement of complete response and is granted Class 2 review 7781 3AMWA Hosts Health Care Conversation With Congressman Kucinich 7776 1AMWA Hosts Health Care Conversation With Congressman Kucinich 7776 2St Jude finds mechanism for faulty protein disposal 7771 1St Jude finds mechanism for faulty protein disposal 7771 2St Jude finds mechanism for faulty protein disposal 7771 3St Jude finds mechanism for faulty protein disposal 7771 4
...r ,According to the American Diabetes Associat... 2002 was estimated to be $132 billion, or one out...ed States. A chronic disease with no cure, diabete..., and gestational) marked by high levels of blood ...on, insulin action, or both. Nearly 20 million Ame...
...,Contributing Editor , ,Positive patient iden...diting bodies for the past few years. Until recen...re were beyond the reach of the average hospital o...th devices that can be integrated into a facilitys...er for small facilities, while others are best for...
Other Medicine Technology:Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control 2Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control 3Managing Preanalytical Processes for Patient Safety 2Managing Preanalytical Processes for Patient Safety 3Managing Preanalytical Processes for Patient Safety 4
Excellent for manipulation of the intraocular lens in the capsular bag. The angled and curved shaft allows the instrument to reach across the implant and catch the optic/ haptic junction to facilitat
Angled shaft with 1.5 mm tip designed to efficiently perform the "Stop and Chop" technique. Round knurled handle. Most popular size or model.
This double ended instrument was designed for delineating and lifting the corneal flap of previously performed lamellar refractive surgery cases.
Used when dislocating the lens. Great for chopping during phacoemulsification. Helpful in ushering the IOL out of eye. Useful to reduce possibility of iris tuck with anterior chamber IOL placement.
Medicine Products: